



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 63755

Title: Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease

Reviewer's code: 04088775

Position: Editorial Board

Academic degree: BMed, FRACP, PhD

Professional title: Doctor, Staff Physician

Reviewer's Country/Territory: Australia

Author's Country/Territory: United States

Manuscript submission date: 2021-02-08

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-02-15 16:38

Reviewer performed review: 2021-02-15 20:01

Review time: 3 Hours

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This is a well written and comprehensive review on immune checkpoint inhibitor colitis and diarrhea when used for the treatment of malignancies including malignancies of the GI tract, and provide some detail on the current data available for the use of these agents in patients with inflammatory bowel disease and malignancies. It is noted that the incidence reported is variable and dependent on the definitions used. I have some small suggestions to improve the paper, particularly for a gastroenterology readership. Suggestion: - Data on the incidence of colitis on patients who underwent endoscopy would be useful to report in the incidence section of the article Minor point: Table 4 - consider rounding the percentages to whole numbers or one decimal place and keep consistent in the table.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 63755

Title: Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease

Reviewer's code: 03580207

Position: Editorial Board

Academic degree: PhD

Professional title: Associate Chief Physician

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2021-02-08

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-02-10 11:47

Reviewer performed review: 2021-02-16 07:03

Review time: 5 Days and 19 Hours

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This is a well written and interesting review about immune checkpoint inhibitor-mediated colitis and diarrhea in gastrointestinal malignancies and inflammatory bowel disease. Suggestion: The mechanism of immune checkpoint inhibitor mediated colitis needs further introduction. The format of the article needs to refer to the requirements of the magazine.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 63755

Title: Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease

Reviewer's code: 03662955

Position: Editorial Board

Academic degree: PhD

Professional title: Chief Physician, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2021-02-08

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-02-16 11:46

Reviewer performed review: 2021-02-16 13:15

Review time: 1 Hour

| | |
|---------------------------------|--|
| Scientific quality | <input checked="" type="checkbox"/> Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish |
| Language quality | <input checked="" type="checkbox"/> Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection |
| Conclusion | <input checked="" type="checkbox"/> Accept (High priority) [] Accept (General priority) [] Minor revision [] Major revision [] Rejection |
| Re-review | [] Yes <input checked="" type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous [] Onymous Conflicts-of-Interest: [] Yes <input checked="" type="checkbox"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This is a well-written paper with a novel topic which merit publication. It reviewed the incidence and risk of IMC in ICI therapy mainly in GI diseases and called the attention to mechanisms underlying this condition. However, the managements were not clearly explored.



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 63755

Title: Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease

Reviewer's code: 04088775

Position: Editorial Board

Academic degree: BMed, FRACP, PhD

Professional title: Doctor, Staff Physician

Reviewer's Country/Territory: Australia

Author's Country/Territory: United States

Manuscript submission date: 2021-02-08

Reviewer chosen by: Chen-Chen Gao

Reviewer accepted review: 2021-04-13 12:17

Reviewer performed review: 2021-04-13 12:23

Review time: 1 Hour

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

The authors have addressed all the suggestions comprehensively and have provided a very good review